![]() ![]() “Secondly, we believe we can leverage our knowledge in manufacturing, to really help in scale and bring down costs. “We can leverage our commercial strength, that’s one,” Schinecker said in an interview. The medical equipment provider earned 50.08 million during the quarter, compared to the consensus estimate of 50 million. The medical equipment provider reported (0.05) EPS for the quarter, missing the consensus estimate of (0.01) by 0.04. GenMark has 7% market share now, he estimated, but Roche aims to significantly boost that four years from now. (NASDAQ:GNMK) issued its quarterly earnings data on Thursday, February, 25th. The market for such tests in 2019 was $800 million annually, Roche diagnostics head Thomas Schinecker said, citing industry figures, adding it should grow by 20% annually to top $2 billion by 2024. GenMark makes “syndromic panel tests” to simultaneously detect multiple pathogens responsible for respiratory illnesses like pneumonia or the dangerous blood infection sepsis, an area Roche has sought to enter to challenge rivals like France’s bioMerieux. The transaction should close in the second quarter. Historical daily share price chart and data for GenMark Diagnostics from 2010 to 2021 adjusted for splits and dividends. 10 share price, before media deal speculation. REUTERS/Arnd Wiegmannīasel-based Roche launched a cash offer for GenMark for $24.05 per share, a premium of 43% on GenMark’s Feb. FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |